CAC Corporation (Head Office: Chuo-ku, Tokyo; President and CEO: Ryota Nishimori; hereinafter called “CAC”) has signed a partnership agreement with rfxcel Corporation (Head Office: Reno, Nevada, USA; CEO: Glenn Abood; hereinafter called “rfxcel”) in the pharmaceutical traceability field.
From now on, CAC, as a distributor of rfxcel, will sell its products in the Japanese market and provide related services such as introduction support and help desks.
In many countries, including the U.S., rfxcel provides a solution for the Life Sciences industry to store and share data tracking information that is serialized across the global supply chain.
In recent years, the threat of counterfeit products in the distribution of pharmaceuticals has been expanding worldwide, and more and more legal restrictions have been placed on these counterfeit products.
In Japan, the Ministry of Health, Labor and Welfare, the pharmaceutical industry, and medical-related organizations are also considering measures against counterfeit drugs. In addition, consideration will be given to establishing traceability across the entire medical field supply chain (pharmaceutical manufacturers, wholesalers, medical institutions, and patients) to ensure efficient and safe medical care, as well as to ensure the safety and security of patients and users.
Taking the opportunity of this agreement, CAC will promote closer collaboration with rfxcel. CAC will also engage in activities that will enable it to properly respond to the changes in the laws and regulations in the pharmaceutical traceability sector in the Japanese market by becoming an active member in conferences related to these various laws and regulations, such as conferences held by the Japan Medical Traceability Promotion Council and GS1 Healthcare Japan. In the Chinese market, we will also consider carrying out activities in cooperation with CAC Shanghai, a group company.
Disclosure: This article includes a client of an Espacio portfolio company